Carcinoma of the Urethra (URETHRECTOMY)
Histopathology Reporting Proforma

Includes the International Collaboration on Cancer reporting dataset denoted by *

Family name

Given name(s)

Date of birth

DD – MM – YYYY

Patient identifiers
e.g. MRN, IHI or NHI (please indicate which)

Date of request

DD – MM – YYYY

S1.03 Accession number

Requesting doctor - name and contact details

*CLINICAL INFORMATION

Previous history of urinary tract disease or distant metastasis

- Information not provided
- No previous history
- Non-invasive papillary
- Carcinoma in situ, flat
- Invasion into lamina propria
- Muscle invasive disease
- Distant metastasis
- Other, specify

Previous therapy

- Information not provided
- No previous therapy
- Radiation therapy
- Chemotherapy, systemic
- Bacillus Calmette-Guerin (BCG)
- Chemotherapy, intravesical, specify

- Other, specify

Other clinical information

OPERATIVE PROCEDURE

- Not specified
- Urethrectomy, partial
- Urethrectomy, complete
- Urethrectomy with cystectomy
- Urethrectomy with cystoprostatectomy
- Urethrectomy with penectomy
- Other, specify

ADDITIONAL SPECIMEN(S) SUBMITTED

- Not submitted

PRINCIPAL CLINICIAN

OTHER COMMENTS

Macroscopic findings

S2.01 SPECIMEN LABELLED AS
**OPERATIVE PROCEDURE**
- Not specified
- Urethrectomy, partial
- Urethrectomy, complete
- Urethrectomy with cystectomy
- Urethrectomy with cystoprostatectomy
- Urethrectomy with penectomy
- Other, specify

**ADDITIONAL SPECIMEN(S) SUBMITTED**

**SPECIMEN MEASUREMENTS**
(Superior to inferior x transverse x anterior to posterior)

**MEASUREMENTS OF OTHER ORGANS**
Organ 1:
- length mm x width mm x thickness mm
Organ 2:
- length mm x width mm x thickness mm
Organ 3:
- length mm x width mm x thickness mm

**TUMOUR FOCALITY**
- Cannot be assessed, specify
- Unifocal
- Multifocal

**TUMOUR DIMENSIONS**
- Cannot be assessed
- No macroscopically visible tumour

Maximum tumour dimension (largest tumour) mm

**GROSS APPEARANCE OF TUMOUR(S)**
(Record for each tumour) (select all that apply)
- Polypoid
- Fungating
- Papillary
- Ulcerated
- Solid and indurated

Tumour 1:
- Polypoid
- Fungating
- Papillary
- Ulcerated
- Solid and indurated

Tumour 2:
- Polypoid
- Fungating
- Papillary
- Ulcerated
- Solid and indurated

Tumour 3:
- Polypoid
- Fungating
- Papillary
- Ulcerated
- Solid and indurated
**S2.08 MACROSCOPIC EXTENT OF INVASION**
(select all that apply)
- Cannot be assessed
- No macroscopically visible tumour
- Non-invasive tumour visible
- Invasion into muscular wall
- Invasion into corpus spongiosum
- Invasion into corpus cavernosum
- Invasion into anterior vaginal wall
- Invasion into prostatic tissue
- Invasion into periprostatic tissue
- Involvement of other adjacent structures, specify

**S2.09 MACROSCOPIC EVIDENCE OF MARGIN INVOLVEMENT**
- Absent
- Present

**MARGIN INVOLVED** (select all that apply)
- Distal
- Proximal
- Deep soft tissue
- Other, specify

**G2.04 APPEARANCE OF UNINVOLVED TISSUE**
- Normal
- Ulcerated
- Erythematous
- Other, specify

**S2.10 LYMPH NODES**
- Not submitted
- Submitted

Site(s) and ....  No. of nodes

**S2.11 BLOCK IDENTIFICATION KEY**

**G2.05 OTHER MACROSCOPIC COMMENTS**

**Microscopic findings**

**S3.01 HISTOLOGICAL TUMOUR TYPE**
- Urothelial carcinoma
- Squamous cell carcinoma
- Adenocarcinoma
- Tumours of Müllerian type
  - Clear cell carcinoma
  - Endometrioid carcinoma
- Neuroendocrine tumour
  - Small cell neuroendocrine carcinoma
  - Large cell neuroendocrine carcinoma
- Other, specify

**Histological sub-type/variant (urothelial carcinoma)**
- Not identified
- Present, specify sub-type/variant and percentage

- Squamous  %
- Glandular  %
- Nested  %
- Micropapillary  %
- Plasmacytoid  %
- Sarcomatoid  %
- Other, specify  %
### S3.02  **NON-INVASIVE CARCINOMA**  
(select all that apply)
- Not identified
- Carcinoma in situ, flat
  - Focal
  - Multifocal
- Papillary carcinoma, non-invasive
- Other, specify

### S3.03  **HISTOLOGICAL GRADE**
- Not applicable
- Cannot be determined

#### Urothelial carcinoma
- Low-grade
- High-grade
- Other, specify

#### Squamous cell ca. or adenocarcinoma
- GX: Cannot be assessed
- G1: Well differentiated
- G2: Moderately differentiated
- G3: Poorly differentiated
- Other, specify

### S3.04  **MICROSCOPIC EXTENT OF INVASION**  
(select all that apply)
- Cannot be assessed
- No evidence of primary tumour

#### Primary tumour (male and female)  
(excluding urothelial carcinoma of prostate)
- Non-invasive papillary
- Carcinoma in situ
- Tumour invades subepithelial connective tissue
- Tumour involves adjacent structures, specify
  - Prostatic stroma
  - Corpus spongiosum
  - Periurethral muscle
  - Corpora cavernosa
  - Other, specify

#### Invasive carcinoma
- Distal
- Proximal
- Deep soft tissue
- Other, specify

#### Carcinoma in situ/non-invasive high-grade urothelial carcinoma
- Distal mucosal
- Proximal mucosa
- Other, specify

### G3.01  **ASSOCIATED EPITHELIAL LESIONS**
- Not identified
- Present, specify

### S3.05  **MICROSCOPIC TUMOUR SITE(S)**

### G3.02  **MICROSCOPIC TUMOUR SIZE**  
(maximum dimension of the largest tumour)

### S3.06  **LYMPHOVASCULAR INVASION**
- Not identified
- Present
- Indeterminate

### S3.07  **MARGIN STATUS**
- Cannot be assessed
- Not involved
- Involved
  - Invasive carcinoma
    - Distal
    - Proximal
    - Deep soft tissue
    - Other, specify
  - Carcinoma in situ/non-invasive high-grade urothelial carcinoma
    - Distal mucosal
    - Proximal mucosa
    - Other, specify
**REGIONAL LYMPH NODES STATUS**
- No regional nodes submitted
- Not involved (record no. of LN examined)
- Involved

Number of lymph nodes examined

No. of positive lymph nodes
- Number cannot be determined

Size of largest metastasis

Location(s) of involved lymph nodes

**HISTOLOGICALLY CONFIRMED DISTANT METASTASES**
- Not identified
- Indeterminate
- Present, specify site(s)

**EXTRANODAL SPREAD**
- Not identified
- Present

**PATHOLOGICAL STAGING AJCC TNM 8TH EDITION (refer below)**

**YEAR AND EDITION OF STAGING SYSTEM**

**DIAGNOSTIC SUMMARY**
Include Operative procedure, Tumour type with different subtypes specified, Tumour grade, Tumour extent, Microscopic tumour site, Lymphovascular invasion, Surgical margin status, Lymph node involvement, Tumour stage, Presence of non-invasive carcinoma

**OVERARCHING COMMENT**

**CARCINOMA OF THE URETHRA (URETHRECTOMY) STRUCTURED REPORTING PROTOCOL (1st Edition 2018)**

**AJCC TNM 8TH EDITION**

m - multiple primary tumours; r - recurrent; y - post neoadjuvant therapy

**Primary tumour (pT)**
- Male penile urethra and female urethra
  - TX Primary tumour cannot be assessed
  - T0 No evidence of primary tumour
  - Ta Non-invasive papillary carcinoma
  - Tis Carcinoma in situ
  - T1 Tumour invades subepithelial connective tissue
  - T2 Tumour invades any of the following: corpus spongiosum, periurethral muscle
  - T3 Tumour invades any of the following: corpus cavernosum, anterior vagina
  - T4 Tumour invades adjacent organs (e.g. invasion of the bladder wall)

**Prostatic urethra**
- Tis Carcinoma in situ involving the prostatic urethra or periurethral or prostatic ducts without stromal invasion
- T1 Tumour invades urethral subepithelial connective tissue immediately underlying the urothelium
- T2 Tumour invades the prostatic stroma surrounding ducts either by direct extension from the urothelial surface or by invasion from prostatic ducts
- T3 Tumour invades the periprostatic fat
- T4 Tumour invades other adjacent organs (e.g. extraprostatic invasion of the bladder wall, rectal wall)

**Regional lymph nodes (pN)**
- NX Regional lymph nodes cannot be assessed
- N0 No regional lymph node metastasis
- N1 Single regional lymph node metastasis in the inguinal region or true pelvis [perivesical, obturator, internal (hypogastric) and external iliac], or presacral lymph node
- N2 Multiple regional lymph node metastasis in the inguinal region or true pelvis [perivesical, obturator, internal (hypogastric) and external iliac], or presacral lymph node

**ANCILLARY STUDIES**
- Not performed
- Performed

Describe

**ANCILLARY FINDINGS**

**COEXISTENT PATHOLOGY**
- None identified
- Present, specify

**OTHER MICROSCOPIC COMMENT**

**EXTRANODAL SPREAD**
- Not identified
- Present

**VERS. 1.0 PROFORMA: CARCINOMA OF THE URETHRA STRUCTURED REPORTING PROTOCOL 1ST EDITION**

---

**Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science and Business Media LLC, www.springerlink.com.**